Clincosm LogoSign in Get a demo

Wait Time Preferences of the US Public for New Drugs: a Discrete Choice Experiment

Sponsor
London School of Economics and Political Science (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05936632
Collaborator
(none)
600
Enrollment
2
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) the public would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of the US public for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Condition or Disease Intervention/Treatment Phase
  • Other: Discrete Choice Experiment (DCE)

Study Design

Study Type:
Observational
Anticipated Enrollment :
600 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
Wait Time Preferences of the US Public for New Drugs With Uncertain Treatment Benefits: a Discrete Choice Experiment
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Preferences for treatment attributes and trade-offs between attributes. [Through study completion, an average of 4-8 weeks.]

    Preferences for different treatment attributes (including clinical uncertainty and wait time), and trade-offs between these, using a study-specific Discrete Choice Experiment (DCE) Questionnaire.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • Individuals previously or currently diagnosed with any type of cancer.

  • Individuals with immediate family members previously or currently diagnosed with any type of cancer.

Exclusion Criteria:
  • Individuals without previous or current diagnosis with any type of cancer (themselves or immediate family members).

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • London School of Economics and Political Science

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Robin Forrest, Principal Investigator, London School of Economics and Political Science
ClinicalTrials.gov Identifier:
NCT05936632
Other Study ID Numbers:
  • 213621
First Posted:
Jul 10, 2023
Last Update Posted:
Jul 10, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Robin Forrest, Principal Investigator, London School of Economics and Political Science
Discrete Choice Experiment

Study Results

No Results Posted as of Jul 10, 2023